Identification of murine T-cell epitopes in Ebola virus nucleoprotein

Virology

Volumn 318, Issue 1, 2004, Pages 224-230

  Simmons, Graham ^a   Lee, Anee ^a   Rennekamp, Andrew J ^a   Fan, Xin ^a   Bates, Paul ^a   Shen, Hao ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CD8 T cells; Ebola; Heterologous prime boost; MHC class I epitope; Vaccine

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; VIRUS NUCLEOPROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EBOLA VIRUS; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS HEMORRHAGIC FEVER; VIRUS IMMUNITY;

EBOLA VIRUS; MURINAE;

EID: 1242297001     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2003.09.016     Document Type: Article

References (21)

1. Arthur R.R. Ebola in Africa - discoveries in the past decade. Euro. Surveill. 7(3):2002;33-36.
2. Baize S., Leroy E.M., Georges-Courbot M.C., Capron M., Lansoud-Soukate J., Debre P., Fisher-Hoch S.P., McCormick J.B., Georges A.J. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5(4):1999;423-426.
3. Basler C.F., Wang X., Muhlberger E., Volchkov V., Paragas J., Klenk H.D., Garcia-Sastre A., Palese P. The ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. U.S.A. 97(22):2000;12289-12294.
4. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 179(Suppl. 1):1999;S248-S258.
5. Geisbert T.W., Hensley L.E., Gibb T.R., Steele K.E., Jaax N.K., Jahrling P.B. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest. 80(2):2000;171-186.
6. Hart M.K. Vaccine research efforts for filoviruses. Int. J. Parasitol. 33(5-6):2003;583-595.
7. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95(5):1998;2509-2514.
8. Leroy E.M., Baize S., Volchkov V.E., Fisher-Hoch S.P., Georges-Courbot M.C., Lansoud-Soukate J., Capron M., Debre P., McCormick J.B., Georges A.J. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 355(9222):2000;2210-2215.
9. Leroy E.M., Baize S., Debre P., Lansoud-Soukate J., Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin. Exp. Immunol. 124(3):2001;453-460.
10. Maecker H.T., Dunn H.S., Suni M.A., Khatamzas E., Pitcher C.J., Bunde T., Persaud N., Trigona W., Fu T.M., Sinclair E., Bredt B.M., McCune J.M., Maino V.C., Kern F., Picker L.J. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods. 255(1-2):2001;27-40.
11. Pushko P., Geisbert J., Parker M., Jahrling P., Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 75(23):2001;11677-11685.
12. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 50(3-4):1999;213-219.
13. Sanchez A., Kiley M.P., Holloway B.P., McCormick J.B., Auperin D.D. The nucleoprotein gene of Ebola virus: cloning, sequencing, and in vitro expression. Virology. 170(1):1989;81-91.
14. Schneider J., Gilbert S.C., Hannan C.M., Degano P., Prieur E., Sheu E.G., Plebanski M., Hill A.V. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 170:1999;29-38.
15. Shen H., Miller J.F., Fan X., Kolwyk D., Ahmed R., Harty J.T. Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity. Cell. 92(4):1998;535-545.
16. Simmons G., Wool-Lewis R.J., Baribaud F., Netter R.C., Bates P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 76(5):2002;2518-2528.
17. Simmons G., Reeves J.D., Grogan C.C., Vandenberghe L.H., Baribaud F., Whitbeck J.C., Burke E., Buchmeier M.J., Soilleux E.J., Riley J.L., Doms R.W., Bates P., Pohlmann S. DC-SIGN and DC-SIGNR bind Ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology. 305(1):2003;115-123.
18. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 408(6812):2000;605-609.
19. van der Most R.G., Harrington L.E., Giuggio V., Mahar P.L., Ahmed R. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology. 296(1):2002;117-124.
20. Vanderzanden L., Bray M., Fuller D., Roberts T., Custer D., Spik K., Jahrling P., Huggins J., Schmaljohn A., Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 246(1):1998;134-144.
21. Wilson J.A., Hart M.K. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J. Virol. 75(6):2001;2660-2664.